In:
Chemotherapy, S. Karger AG, Vol. 48, No. 4 ( 2002), p. 205-210
Abstract:
〈 i 〉 Background: 〈 /i 〉 Previous studies have reported a synergistic effect between irinotecan and cisplatin. We have conducted a phase I trial combining these agents to find the optimal dose of irinotecan in combination with a fixed dose of cisplatin. 〈 i 〉 Methods: 〈 /i 〉 Patients with advanced solid tumors, aged ≤75 years, performance status ≤2, and adequate organ function were enrolled in this study. They were treated at 4-week intervals with irinotecan plus 20 mg/m 〈 sup 〉 2 〈 /sup 〉 cisplatin on days 1, 8, and 15. The starting dose of irinotecan of 40 mg/m 〈 sup 〉 2 〈 /sup 〉 was escalated in 10 mg/m 〈 sup 〉 2 〈 /sup 〉 increments until a maximum dose of 90 mg/m 〈 sup 〉 2 〈 /sup 〉 was reached. 〈 i 〉 Results: 〈 /i 〉 The recommended dose for phase II studies is 90 mg/m 〈 sup 〉 2 〈 /sup 〉 of irinotecan and 20 mg/m 〈 sup 〉 2 〈 /sup 〉 of cisplatin on days 1, 8, and 15. Overall response to the chemotherapy was 35% (95% confidential interval, 19.2–54.6%). 〈 i 〉 Conclusion: 〈 /i 〉 This combination seems to be active against lung cancer with acceptable toxicity. A phase II study is now ongoing.
Type of Medium:
Online Resource
ISSN:
0009-3157
,
1421-9794
Language:
English
Publisher:
S. Karger AG
Publication Date:
2002
detail.hit.zdb_id:
1482111-4
SSG:
15,3
Permalink